These options, developed by Novo Nordisk and Eli Lilly, respectively, have dominated the conversation because they help people lose an average of 15% to 20% of their body weight
"About 50% of large employers have chosen to cover it for weight management
For patients seeking weight-loss medications outside of brand-name versions like Ozempic or Wegovy, compounded options can provide a more affordable alternative
Obesity and overweight, which are common in patients with DM2, are a factors that favor the development/progression of CKD through both direct and indirect effects.69 Although the precise mechanisms the association between obesity and CKD are not totally defined it has been proposed that hypertension, glomerular hyperfiltration, hyperglycemia, lipid toxicity, inflammation or the role of adipose tissue and its adipokines are involved.70 Weight reduction by bariatric surgery, pharmacological treatment or dietary measures are associated with a nephroprotective effect,7173 so that weight reduction is a fundamental objective in the nephroprotection of patients with DKD